9th Jan 2012 18:27
Notification of Transactions of Directors, Persons Discharging
Managerial Responsibility or Connected Persons
The Administrators of the GlaxoSmithKline 2009 Deferred Annual Bonus Plan (the "Plan") notified the Company and the under-mentioned persons on 9 January 2012 of an increase in their notional interests in Ordinary shares and ADRs at a price of 1483 pence per share and $46.35 per share following the re-investment of dividends paid to shareholders on 5 January 2012.
Sir Andrew Witty | Acquisition of 674 Ordinary shares under the personal contribution element of the Plan. |
Mr S M Bicknell
Mrs D P Connelly
Mr D S Redfern
Dr M M Slaoui
Ms C Thomas
Mr D E Troy
Dr P J T Vallance
| Acquisition of 674 Ordinary shares under the matching element of the Plan (Company contribution).
Acquisition of 79 Ordinary shares under the personal contribution element of the Plan.
Acquisition of 79 Ordinary shares under the matching element of the Plan (Company contribution).
Acquisition of 45 ADRs under the personal contribution element of the Plan.
Acquisition of 45 ADRs under the matching element of the Plan (Company contribution).
Acquisition of 89 Ordinary shares under the personal contribution element of the Plan.
Acquisition of 89 Ordinary shares under the matching element of the Plan (Company contribution).
Acquisition of 225 ADRs under the personal contribution element of the Plan.
Acquisition of 225 ADRs under the matching element of the Plan (Company contribution).
Acquisition of 19 Ordinary shares under the personal contribution element of the Plan.
Acquisition of 19 Ordinary shares under the matching element of the Plan (Company contribution).
Acquisition of 112 ADRs under the personal contribution element of the Plan.
Acquisition of 112 ADRs under the matching element of the Plan (Company contribution).
Acquisition of 177 Ordinary shares under the personal contribution element of the Plan.
Acquisition of 177 Ordinary shares under the matching element of the Plan (Company contribution).
|
The notional dividends accrued will be paid out in proportion to the percentage of the participant's deferred annual bonus holdings that will vest following the end of the relevant three year measurement period.
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
9 January 2012
Related Shares:
Glaxosmithkline